Bronchodilators Market Shows Strong Growth with Leading Players
Bronchodilators are medications that make breathing easier
by opening the airways of the lung by relaxing bronchial muscles. They are used
to treat various respiratory problems such as asthma, COPD, and other allergic
reactions that cause breathing problems.The growth of the global
bronchodilators market is driven by various factors such as increase in
prevalence of pulmonary disorders, increasing geriatric population and
increasing mergers and acquisitions by prominent players in the market.
However, side effects associated with bronchodilators and government
regulations related to the safety & efficacy of the bronchodilators are
projected to hamper the growth of the global bronchodilators market.
According to MRFR analysis, Bronchodilators
Market is expected to register a CAGR of 5.30% during the forecast period
of 2019 to 2025 and is expected to reach USD 2,484 Million by 2025.The global
bronchodilators market is currently dominated by several market players. The
key players are involved in product launches and strategic collaborations to
strengthen their market positions. For instance, in April 2019, Cipla
Technologies entered into agreement with Pulmatrix Inc. to co-develop a
formulation for the treatment of allergic bronchopulmonary aspergillosis (ABPA)
in patients with asthma.
Request
Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/8453
Segmentation
The global bronchodilators market has been segmented based
on drug type, disease, mode of action, and route of administration.
The market, based on drug type, has been divided into
adrenergic drugs, anticholinergics, a phosphodiesterase inhibitor, and
combination drugs.
The adrenergic segment is likely to be the largest during
the review period as they are the most potent bronchodilators approved for
clinical use in asthma and obstructive lung disease. The combination drugs segment
is predicted to be the fastest-growing segment. These combination drugs are
used if COPD and asthma are not controlled with monotherapy. These combinations
involving two long-acting bronchodilators with differing modes of action.
The global bronchodilators market has been segmented, on the
basis of disease, into asthma, COPD, and others. The asthma segment is expected
to hold the majority share of the market, owing to the rise in patients
affected with asthma. The COPD segment is expected to be the fastest-growing as
bronchodilators are primary treatment for chronic obstructive pulmonary disease
(COPD) as they help to alleviate bronchial obstruction and airflow limitation.
In terms of mode of action, the global bronchodilators
market has been segmented into short-acting bronchodilators and long-acting
bronchodilators. Short-acting bronchodilators are expected to be the largest
segment, owing to its ability to provide quick relief from sudden, unexpected
attacks of breathlessness.
The route of administration of the market is oral and
parenteral. The oral route of administration segment is expected to hold the
largest share of the market due to the advantages such as ease and simplicity
of administration along with control of delivered dose.
Key Players
Some of the key players in the Global Bronchodilators Market
are GlaxoSmithKline (UK), Novartis AG (Switzerland), Merck & Co., Inc.
(US), Abbott Laboratories (US), Boehringer Ingelheim GmbH (Germany),
AstraZeneca plc (UK), F. Hoffmann LA-Roche AG (Switzerland), Teva
Pharmaceutical (Israel) and Pfizer Inc. (US) among others.
Regional Analysis
The market has been divided, by region, into the Americas,
Europe, Asia-Pacific, and the Middle East & Africa. The Americas are
expected to be the largest market owing to the rising per capita healthcare
expenditure. The bronchodilators market in the Americas has further been
branched into North America and Latin America, with the North American market
divided into the US and Canada. The European bronchodilators market has been
categorized as Western Europe and Eastern Europe. The Western European market
has further been classified as Germany, France, the UK, Italy, Spain, and the
rest of Western Europe. The bronchodilators market in Asia-Pacific has been
segmented into Japan, China, India, South Korea, Australia, and the rest of
Asia-Pacific. Due to the increasing prevalence of respiratory disorders and the
increasing pool of patient population, the market in Asia-Pacific is expected
to be the fastest-growing. The bronchodilators market in the Middle East &
Africa has been divided into the Middle East and Africa.
Browse Detailed TOC
with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/bronchodilators-market-8453
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to
unravel the complexity of various industries through our Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR
team have supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Comments
Post a Comment